EU and France Invest €10.2 Million to Strengthen Nigeria’s Pharmaceutical Manufacturing Capacity

The European Union (EU) and France have announced a €10.2 million investment to enhance Nigeria’s pharmaceutical manufacturing capacity, marking a key step toward health sovereignty and industrial transformation. The initiative underscores Europe’s commitment to supporting Africa’s self-reliance in medicine production and quality improvement.

Investment under the MAV+ Initiative

The funding, part of the Global Gateway’s Manufacturing and Access to Vaccines, Medicines and Health Technologies (MAV+) Initiative, will support the Quality Uplift for Advancing Local Industry in Medicine Standards (Qualimeds Nigeria) project, a 44-month program (2025–2028) focused on modernizing pharmaceutical production, improving GMP standards, and expanding access to essential medicines. The EU will provide €10 million, while France’s Ministry for Europe and Foreign Affairs will contribute €200,000, in collaboration with Nigeria’s Ministry of Health, NIPRD, and other key partners.

Advancing Health Sovereignty and Industrial Growth
EU Ambassador to Nigeria and ECOWAS Gautier Mignot said the investment reaffirms Europe’s commitment to Africa’s health resilience and economic growth, emphasizing that the partnership will make healthcare in Nigeria “life-saving, sustainable, and accessible for all, while creating jobs and opportunities.” The Qualimeds Nigeria project is expected to strengthen local manufacturing standards, create employment, and expand access to affordable, high-quality medicines, advancing Nigeria’s Universal Health Coverage (UHC) goals.